BR112018072701A2 - métodos de tratamento de leucemia mieloide aguda e mieloma múltiplo usando células exterminadoras naturais - Google Patents
métodos de tratamento de leucemia mieloide aguda e mieloma múltiplo usando células exterminadoras naturaisInfo
- Publication number
- BR112018072701A2 BR112018072701A2 BR112018072701-6A BR112018072701A BR112018072701A2 BR 112018072701 A2 BR112018072701 A2 BR 112018072701A2 BR 112018072701 A BR112018072701 A BR 112018072701A BR 112018072701 A2 BR112018072701 A2 BR 112018072701A2
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- methods
- myeloid leukemia
- natural killer
- acute myeloid
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 8
- 210000000822 natural killer cell Anatomy 0.000 title abstract 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title abstract 3
- 208000034578 Multiple myelomas Diseases 0.000 title abstract 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 title abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 4
- 230000003169 placental effect Effects 0.000 abstract 3
- 210000000130 stem cell Anatomy 0.000 abstract 3
- 238000012258 culturing Methods 0.000 abstract 1
- 210000004700 fetal blood Anatomy 0.000 abstract 1
- 230000003394 haemopoietic effect Effects 0.000 abstract 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
- 210000005259 peripheral blood Anatomy 0.000 abstract 1
- 239000011886 peripheral blood Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
- C12N2501/91—Heparin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
são aqui fornecidos métodos de tratamento da leucemia mieloide aguda (aml) e do mieloma múltiplo (mm) por administração de uma quantidade eficaz de uma população celular compreendendo células exterminadoras naturais, nas quais a população celular compreendendo células exterminadoras naturais é produzida por um método de três estágios compreendendo a cultura de uma população de células-tronco ou progenitoras hematopoéticas em meios compreendendo fatores de mobilização de células-tronco, por exemplo, métodos de três estágios de produção de células nk em meios compreendendo fatores de mobilização de células-tronco partindo de células-tronco hematopoéticas ou progenitoras de células placentárias, por exemplo perfusado placentário (por exemplo, perfusado placentário humano) ou outros tecidos, por exemplo, sangue do cordão umbilical ou sangue periférico. além disso, são aqui fornecidos métodos de utilização das células nk produzidas pelos métodos de três estágios aqui proporcionados para suprimir a proliferação de células de leucemia mieloide aguda. em certas modalidades, as células nk produzidas pelos métodos de três estágios aqui descritos são utilizadas em combinação com il-2.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662333186P | 2016-05-07 | 2016-05-07 | |
US201662333187P | 2016-05-07 | 2016-05-07 | |
US62/333,187 | 2016-05-07 | ||
US62/333,186 | 2016-05-07 | ||
US201662415918P | 2016-11-01 | 2016-11-01 | |
US201662415954P | 2016-11-01 | 2016-11-01 | |
US62/415,954 | 2016-11-01 | ||
US62/415,918 | 2016-11-01 | ||
PCT/US2017/031255 WO2017196657A1 (en) | 2016-05-07 | 2017-05-05 | Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018072701A2 true BR112018072701A2 (pt) | 2019-02-19 |
Family
ID=60267345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018072701-6A BR112018072701A2 (pt) | 2016-05-07 | 2017-05-05 | métodos de tratamento de leucemia mieloide aguda e mieloma múltiplo usando células exterminadoras naturais |
Country Status (15)
Country | Link |
---|---|
US (1) | US11180731B2 (pt) |
EP (1) | EP3452063A4 (pt) |
JP (2) | JP2019519486A (pt) |
KR (1) | KR20190005964A (pt) |
CN (1) | CN109843304A (pt) |
AU (2) | AU2017262581A1 (pt) |
BR (1) | BR112018072701A2 (pt) |
CA (1) | CA3023239A1 (pt) |
CO (1) | CO2018012923A2 (pt) |
IL (1) | IL262775A (pt) |
MX (1) | MX2018013565A (pt) |
NZ (1) | NZ747910A (pt) |
SG (2) | SG10201912837RA (pt) |
WO (1) | WO2017196657A1 (pt) |
ZA (1) | ZA201807431B (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019215034C1 (en) | 2018-02-01 | 2022-01-06 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
WO2020252464A1 (en) * | 2019-06-14 | 2020-12-17 | Celularity Inc. | Populations of natural killer cells for treating cancers |
CN111727961B (zh) * | 2020-08-10 | 2020-12-01 | 医微细胞生物技术(广州)有限公司 | 一种牙髓干细胞冻存液及其冻存方法 |
TW202237826A (zh) | 2020-11-30 | 2022-10-01 | 瑞士商克里斯珀醫療股份公司 | 基因編輯的自然殺手細胞 |
EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
CN114015653A (zh) * | 2021-12-15 | 2022-02-08 | 山东省齐鲁干细胞工程有限公司 | 一种冻存脐带血来源的nk细胞及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07135969A (ja) * | 1993-11-18 | 1995-05-30 | Rikagaku Kenkyusho | ナチュラルキラー細胞の前駆細胞及びその分化増殖法 |
PE20100362A1 (es) * | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
WO2012128622A1 (en) * | 2011-03-18 | 2012-09-27 | Ipd-Therapeutics B.V. | Generation of nk cells and nk-cell progenitors |
SG11201404241SA (en) * | 2012-01-27 | 2014-08-28 | Univ Montreal | Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells |
CA2864283C (en) | 2012-02-08 | 2020-11-03 | Jan Spanholtz | Ex vivo nk cell differentiation from cd34+ hematopoietic cells |
CA2881792C (en) * | 2012-08-13 | 2024-02-27 | Anthrogenesis Corporation | Natural killer cells and uses thereof |
CN106459914B (zh) * | 2014-05-15 | 2020-11-06 | 新加坡国立大学 | 经修饰的自然杀伤细胞及其用途 |
-
2017
- 2017-05-05 CA CA3023239A patent/CA3023239A1/en active Pending
- 2017-05-05 AU AU2017262581A patent/AU2017262581A1/en not_active Abandoned
- 2017-05-05 MX MX2018013565A patent/MX2018013565A/es unknown
- 2017-05-05 SG SG10201912837RA patent/SG10201912837RA/en unknown
- 2017-05-05 EP EP17796602.5A patent/EP3452063A4/en active Pending
- 2017-05-05 JP JP2018558214A patent/JP2019519486A/ja active Pending
- 2017-05-05 US US16/099,676 patent/US11180731B2/en active Active
- 2017-05-05 CN CN201780041903.6A patent/CN109843304A/zh active Pending
- 2017-05-05 SG SG11201809858RA patent/SG11201809858RA/en unknown
- 2017-05-05 KR KR1020187035673A patent/KR20190005964A/ko not_active IP Right Cessation
- 2017-05-05 NZ NZ747910A patent/NZ747910A/en unknown
- 2017-05-05 BR BR112018072701-6A patent/BR112018072701A2/pt unknown
- 2017-05-05 WO PCT/US2017/031255 patent/WO2017196657A1/en unknown
-
2018
- 2018-11-05 IL IL262775A patent/IL262775A/en unknown
- 2018-11-06 ZA ZA2018/07431A patent/ZA201807431B/en unknown
- 2018-11-28 CO CONC2018/0012923A patent/CO2018012923A2/es unknown
-
2022
- 2022-04-18 JP JP2022068180A patent/JP2022095927A/ja active Pending
- 2022-12-13 AU AU2022287584A patent/AU2022287584A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3452063A1 (en) | 2019-03-13 |
KR20190005964A (ko) | 2019-01-16 |
JP2022095927A (ja) | 2022-06-28 |
MX2018013565A (es) | 2019-08-21 |
SG10201912837RA (en) | 2020-02-27 |
CA3023239A1 (en) | 2017-11-16 |
WO2017196657A1 (en) | 2017-11-16 |
US11180731B2 (en) | 2021-11-23 |
EP3452063A4 (en) | 2020-01-08 |
AU2022287584A1 (en) | 2023-02-02 |
CO2018012923A2 (es) | 2018-12-14 |
NZ747910A (en) | 2023-02-24 |
US20190153389A1 (en) | 2019-05-23 |
JP2019519486A (ja) | 2019-07-11 |
ZA201807431B (en) | 2021-09-29 |
IL262775A (en) | 2018-12-31 |
SG11201809858RA (en) | 2018-12-28 |
AU2017262581A1 (en) | 2019-01-03 |
CN109843304A (zh) | 2019-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018072701A2 (pt) | métodos de tratamento de leucemia mieloide aguda e mieloma múltiplo usando células exterminadoras naturais | |
BR112017014269A2 (pt) | células exterminadoras naturais e usos das mesmas | |
MY201637A (en) | Natural killer cells and ilc3 cells and uses thereof | |
BR112017004349A2 (pt) | terapia com gene de globina para o tratamento de hemoglobinopatias | |
BR112016023523A2 (pt) | produtos de células t modificados em gene de composição definida | |
BR112017010490A2 (pt) | roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano. | |
BR112015024605A2 (pt) | sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo | |
BR112015011933A2 (pt) | composições bacterianas sinérgicas e métodos de produção e uso das mesmas | |
PH12021551241A1 (en) | Expansion of natural killer cells and ilc3 cells with novel aromatic compounds | |
BRPI0618486A2 (pt) | uso de células progenitoras multipotentes em adultos | |
BR112017014345A2 (pt) | populações de células do rpe e métodos de gerar as mesmas | |
MX2019010382A (es) | Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva. | |
BR112018011327A2 (pt) | usos de populações expandidas de células-tronco/progenitoras hematopoiéticas | |
MX2020011254A (es) | Celulas t car anti-bcma para agotamiento de celulas de plasma. | |
PH12019500643A1 (en) | Antibodies that bind interleukin-2 and uses thereof | |
MX2020005849A (es) | Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos. | |
PH12021551100A1 (en) | Dried biological compositions and methods thereof | |
BR112017014098A2 (pt) | métodos de isolamento de plaquetas | |
JP2016506968A5 (pt) | ||
BR112017019189A2 (pt) | agente terapêutico celular para tratamento de câncer e terapia de combinação com o mesmo | |
WO2018140850A3 (en) | T cells derived from umbilical cord blood | |
IL257929B1 (en) | Methods for the treatment of multiple myeloma and plasma cell leukemia using T-cell therapy | |
MX2020011500A (es) | Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas. | |
IL283882A (en) | Preparations and methods for the treatment of (cutaneous t cell lymphoma (ctcl | |
ZA201907623B (en) | T cells with reduced surface fucosylation and methods of making and using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |